FIELD: medicine; experimental medicine; traumatology.
SUBSTANCE: invention can be used to prevent the development of skeletal muscle fatigue. The method includes injection into the body against the background of a 7-day functional unloading of the selective activator of SERCA receptors (Ca2+-ATPase of the sarco/endoplasmic reticulum) — CDN1163 at a dosage of 50 mg/kg daily for 7 days.
EFFECT: preventing the increased muscle fatigue by activating SERCA receptors and reducing the level of tropomyosin oxidation (an indicator of oxidative stress), maintaining the proportion of “slow” fatigue-resistant muscle fibres, preventing an increase in the number of “fast” fibres, as well as mitochondrial DNA and protein.
1 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF MAINTAINING THE STRENGTH AND RIGIDITY OF THE POSTURAL MUSCLES OF MAMMALS DURING THEIR FUNCTIONAL UNLOADING | 2022 |
|
RU2800317C1 |
| METHOD OF PREVENTING ATROPHY OF SKELETAL MUSCLES DURING THEIR FUNCTIONAL UNLOADING | 2022 |
|
RU2797216C1 |
| METHOD FOR PREVENTION OF SKELETAL MUSCLE ATROPHY AFTER FUNCTIONAL UNLOADING | 2012 |
|
RU2481105C1 |
| METHOD FOR PREVENTING AND REDUCING DESTRUCTION OF CYTOSKELETAL PROTEINS OF ATROPHIED SKELETAL MUSCLES CAUSED BY HYPOKINESIA AND/OR DISCHARGE BY GRAVITY | 2010 |
|
RU2444354C2 |
| METHOD FOR PREVENTING AND REDUCING DESTRUCTION OF SKELETAL PROTEINS OF ATROPHIED SKELETAL MUSCLES CAUSED BY HYPOKINESIA AND/OR DISCHARGE BY GRAVITY | 2013 |
|
RU2517576C1 |
| METHOD FOR PREVENTING AND REDUCING DESTRUCTION OF SKELETAL PROTEINS OF ATROPHIED SKELETAL MUSCLES CAUSED BY HYPOKINESIA AND/OR DISCHARGE BY GRAVITY | 2013 |
|
RU2517259C1 |
| USE OF VX 745 TO PREVENT SKELETAL MUSCLE ATROPHY WITH FUNCTIONAL DISCHARGE | 2019 |
|
RU2714923C1 |
| INHIBITOR OF EXERTIONAL CYTOSKELETAL PROTEOLYSIS OF SKELETAL MUSCLES | 2008 |
|
RU2389486C1 |
| METHOD OF PREVENTING CYTOSCELETAL PROTEINS DESTRUCTION IN SCELETAL MUSCLES WITHIN ECCENTRIC LOAD | 2008 |
|
RU2391968C1 |
| PHYTOECDYSONES AND DERIVATIVES THEREOF FOR USE IN TREATING NEUROMUSCULAR DISEASES | 2020 |
|
RU2820936C2 |
